EcoDrugPlus

Folate Receptor Alpha

Ensembl ID : ENSMZEG00005007500
Gene Symbol: LOC101484157
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSMZEG00005007930
Gene Symbol: LOC101467997
2 Cross references
338 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSMZEG00005026242
Gene Symbol: LOC101469345
3 Cross references
320 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSMZEG00005015874
Gene Symbol: FRK
3 Cross references
202 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSMZEG00005008574
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin-3

Ensembl ID : ENSMZEG00005010412
Gene Symbol: LOC101468242
3 Cross references
220 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1

Ensembl ID : ENSMZEG00005008540
Gene Symbol: LOC101464593
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2

Ensembl ID : ENSMZEG00005005781
Gene Symbol: LOC101465993
2 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-6

Ensembl ID : ENSMZEG00005011940
Gene Symbol: LOC101464546
3 Cross references
69 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Beta-2

Ensembl ID : ENSMZEG00005011954
Gene Symbol: LOC101464081
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha4 Subunit

Ensembl ID : ENSMZEG00005005757
Gene Symbol: GABRA4
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSMZEG00005012552
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).